NASDAQ: BNOX - Bionomics Limited

Altı ay boyunca karlılık: -49.58%
Sektör: Healthcare

Promosyon programı Bionomics Limited

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.

daha fazla ayrıntı
It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2021-12-16
ISIN US09063M2052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://www.bionomics.com.au
Цена ао 0.278
Günlük fiyat değişimi: -9.44% (4.45)
Haftalık fiyat değişimi: +38.26% (2.9148)
Aylık fiyat değişimi: +12.7% (3.576)
3 ayda fiyat değişimi: -47.51% (7.6776)
Altı ayda fiyat değişimi: -49.58% (7.9932)
Yıllık fiyat değişimi: +172.3% (1.48)
3 yılda fiyat değişimi: -68.64% (12.85)
5 yılda fiyat değişimi: 0% (4.03)
10 yılda fiyat değişimi: 0% (4.03)
Yılbaşından bu yana fiyat değişimi: +20.33% (3.3492)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 4290.29 1
P/BV 4.91 3
P/E 0 0
EV/EBITDA -7.47 0
Toplam: 2.75

Yeterlik

İsim Anlam Seviye
ROA, % -66284.99 0
ROE, % -117366.73 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.027 10
Toplam: 9.6

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % -99.32 0
karlılık Ebitda, % -88.49 0
karlılık EPS, % 2304445.45 10
Toplam: 4
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Lynx1 Capital Management Lp 824305 10.1
Point72 Asset Management, L.P. 331000 4.06
Morgan Stanley 94967 1.16
Two Sigma Investments, LP 31272 0.38
XTX Topco Ltd 11834 0.15
Tower Research Capital LLC (TRC) 1606 0.02
Rhumbline Advisers 505 0.01
UBS Group AG 329 0
Aspire Private Capital, LLC 200 0



Süpervizör İş unvanı Ödeme Doğum yılı
Dr. Spyridon Papapetropoulos M.D., Ph.D. CEO, President & Director 510.37k 1973 (52 yıl)
Mr. Timothy M. Cunningham CPA, M.B.A. Chief Financial Officer N/A 1963 (62 yıl)
Dr. Julie Kerner Ph.D. Senior Vice President of Business Operations N/A
Ms. Elizabeth Doolin Senior Vice President of Clinical Development 1965 (60 yıllar)
Dr. Mark A. Smith M.D., Ph.D. Chief Medical Officer 1955 (70 yıllar)

Adres: Australia, Eastwood, 200 Greenhill Road - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.bionomics.com.au